Abridge is a generative AI company building enterprise-grade clinical documentation tools for hospitals and health systems. Founded in 2018 in Pittsburgh by cardiologist Shiv Rao and machine-learning researcher Zachary Lipton, it has become one of the most widely deployed ambient AI scribes in US healthcare.
The platform listens to patient-clinician conversations through a mobile or in-room device and produces structured clinical notes, billing codes, and patient-friendly summaries in near real time. Abridge layers context-aware retrieval and evidence linking on top of its speech and language models, and it embeds directly into Epic, the dominant US electronic health record, as well as Oracle Health and other major EHRs.
Abridge has raised more than $460 million in total disclosed funding. In February 2025 it closed a $250M Series D at a $2.75B valuation, then followed in June 2025 with a $300M Series E led by Andreessen Horowitz with participation from Khosla Ventures, doubling its valuation to $5.3B in roughly four months. The company reported approximately $117M in contracted annual recurring revenue in Q1 2025.
Traction is concentrated in large integrated delivery networks. Abridge is deployed across more than 150 health systems including Kaiser Permanente, Mayo Clinic, UPMC, Johns Hopkins, and Yale New Haven Health, and is used by tens of thousands of clinicians across specialties. The company expanded from physician notes into nursing documentation, revenue cycle workflows, and clinical decision support during 2024-2025.
Compared with rivals such as Nuance DAX (Microsoft), Suki, Nabla, and DeepScribe, Abridge differentiates on the depth of its Epic integration, its focus on enterprise-grade compliance and SOC 2 / HITRUST controls, and its move beyond simple note generation into revenue cycle and decision support. Its main risk is intensifying competition from Microsoft and EHR vendors building native ambient scribe tooling.